Bill 119 s 1040, also known as the "Product Hopping Prohibition Act," aims to make changes to the Federal Trade Commission Act in order to prevent a practice known as product hopping. Product hopping occurs when a pharmaceutical company makes minor changes to a drug in order to extend its patent protection and prevent generic competition.
The bill seeks to prohibit this practice by requiring pharmaceutical companies to prove that any changes made to a drug are truly beneficial to patients and not just a way to stifle competition. This would help to ensure that consumers have access to more affordable generic versions of medications.
In addition to addressing product hopping, the bill also includes provisions for other purposes related to competition and consumer protection. These provisions are aimed at promoting fair competition in the pharmaceutical industry and protecting consumers from anti-competitive practices.
Overall, Bill 119 s 1040 is designed to promote competition, lower drug prices, and protect consumers from unfair practices in the pharmaceutical industry. It is an important piece of legislation that aims to improve access to affordable medications for all Americans.